ArticleScientific reports2025
Protective effect of tanshinone IIA against Listeria monocytogenes infection in vitro and in vivo.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Listeriolysin O (LLO) is a vital virulence factor for the intracellular replication and pathogenesis of Listeria monocytogenes. The search for an effective LLO activity inhibitor as an alternative approach for the treatment of L. monocytogenes infection has attracted great attention. Tanshinone IIA (Tan IIA) is a bioactive compound in the traditional Chinese medicine "Danshen". In this study, the protective effect of Tan IIA against L. monocytogenes infection was investigated using hemolysis test, LDH release method, oligomerization assay and molecular dynamics simulation in combination with in vivo mouse experiment. Tan IIA significantly inhibited the pore-forming activity of LLO by forming a stable LLO - Tan IIA complex. Meanwhile, Tan IIA concentration-dependently decreased the cytotoxicity of L. monocytogenes toward J774 and BeWo cells with the inhibitory rates being 41.3% and 54.5% at concentration of 8 µg/mL, respectively. Furthermore, the intracellular growth of L. monocytogenes was also inhibited by Tan IIA in an LLO-dependent manner. Of note, Tan IIA (80 mg/kg) protected mice against L. monocytogenes infections with the increased survival rate of 26.7%, reduced bacterial loads, alleviated tissue damages, and diminished inflammation. In conclusion, Tan IIA might be a promising anti-virulence candidate for the treatment of L. monocytogenes infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.